Updates in the medical management of Parkinson disease
暂无分享,去创建一个
[1] J. Friedman,et al. Long‐term outcome of clozapine use for psychosis in parkinsonian patients , 2004, Movement disorders : official journal of the Movement Disorder Society.
[2] C. Adler,et al. Efficacy of Rivastigmine for Cognitive Symptoms in Parkinson Disease With Dementia , 2009, The neurologist.
[3] J. Kane,et al. Controlled, Double-blind Investigation of the Clozapine Discontinuation Symptoms With Conversion to Either Olanzapine or Placebo , 1999 .
[4] O Rascol. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group , 2000 .
[5] Werner Poewe,et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. , 2009, The New England journal of medicine.
[6] John Seibyl,et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. , 2000, JAMA.
[7] A. Lang,et al. Impulse control disorders in parkinson disease: A multicenter case–control study , 2011, Annals of neurology.
[8] Parkinson Study Group,et al. Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patients , 1997, Annals of neurology.
[9] M. Okun,et al. Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.
[10] M. Muenter,et al. Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.
[11] D. Brooks,et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.
[12] B. Snow,et al. The Effect of Amantadine on Levodopa-induced Dyskinesias in Parkinson's Disease: A Double-blind, Placebo-controlled Study , 2000, Clinical neuropharmacology.
[13] G. Deuschl,et al. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and Austria (Celomen study) , 2002, Acta neurologica Scandinavica.
[14] W Poewe,et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial , 2005, The Lancet.
[15] S. Buyske,et al. A controlled trial of antidepressants in patients with Parkinson disease and depression , 2009, Neurology.
[16] A. Lees,et al. Ten-year follow-up of three different initial treatments in de-novo PD: A randomized trial , 2001 .
[17] W. Oertel,et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study , 2006, Movement disorders : official journal of the Movement Disorder Society.
[18] L. Golbe,et al. Parkinson's Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician , 2001 .
[19] J. Larsen,et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations , 1998, Neurology.
[20] L. Defebvre,et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study , 2008, Movement disorders : official journal of the Movement Disorder Society.
[21] I. McKeith,et al. SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders , 2003, Movement disorders : official journal of the Movement Disorder Society.
[22] N P Quinn,et al. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? , 2000, Journal of neurology, neurosurgery, and psychiatry.
[23] S. Leurgans,et al. Hallucinations and sleep disorders in PD , 2005, Neurology.
[24] S. Konitsiotis,et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. , 1999, Archives of neurology.
[25] F. Stocchi,et al. Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson’s patients , 2004, Journal of Neural Transmission.
[26] N. Volkow,et al. Slow recovery of human brain MAO B after L‐Deprenyl (Selegeline) withdrawal , 1994, Synapse.
[27] Mahlon R DeLong,et al. Prevalence, etiology, and treatment of depression in Parkinson’s disease , 2003, Biological Psychiatry.
[28] John G Nutt,et al. Clinical practice. Diagnosis and initial management of Parkinson's disease. , 2005, The New England journal of medicine.
[29] G. Fénelon,et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. , 2000, Brain : a journal of neurology.
[30] John G. Nutt,et al. Diagnosis and Initial Management of Parkinson's Disease , 2005 .
[31] J. Kane,et al. Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group. , 1999, Journal of clinical psychopharmacology.
[32] D. Brooks,et al. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study , 2003, Journal of neurology, neurosurgery, and psychiatry.
[33] A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. , 2005, Archives of neurology.